Figure 2
From: Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
Changes in circulating cytokines in sera following rAAV2- IL27 treatment. Ten mice (five male and five female) were treated systemically with saline (negative control) or rAAV2-LacZ (vector control) or rAAV2-IL27 per treatment for each disease stage (6-week-old mice for pre-disease stage and 14-week-old mice for clinical disease stage). Each mouse was injected with 2 × 1010 vector genome of rAAV2-IL27 or rAAV2-LacZ in 50 μL of saline via intravenous line in tail veins. Sera were collected 1 week before (-1, baseline) and 8, 12, and 20 weeks after the treatment of pre-disease and clinical disease mice groups. Levels of cytokines (IL-27, IL-17, and IL-10) were detected by enzyme-linked immunosorbent assay. IL-27 levels in pre-disease (A) and clinical-disease (B) stages. IL-17 levels in pre-disease (C) and clinical-disease (D) stages. IL-10 levels in pre-disease (E) and clinical-disease (F) stages. Values are mean ± standard error of the mean (n = 7). *P < 0.05 rAAV2-IL27 group versus rAAV2-LacZ or saline groups by one-way analysis-of-variance test; **P < 0.01. IL, interleukin; IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; Saline, saline-treated groups.